导航

| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | 20.76% | 260/4773 |
| 近一周 | -2.33% | 1821/5462 |
| 近一月 | -9.26% | 4651/5421 |
| 近一季 | -12.32% | 3828/5209 |
| 近半年 | 17.97% | 209/4920 |
| 近一年 | 25.13% | 275/4366 |
| 近两年 | 129.49% | 335/2954 |
| 近三年 | 72.10% | 286/2253 |
| 成立以来 | 47.22% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-5.17% 3776/4961 |
71.12% 263/5312 |
- - |
- - |
| 2025 | 39.55% 818/4813 |
-2.48% 2895/3635 |
0.64% 2598/4076 |
45.84% 571/4524 |
-2.49% 3157/4813 |
| 2024 | 8.97% 1501/3463 |
-5.54% 1924/2808 |
-6.36% 1921/3014 |
17.74% 1128/3129 |
4.63% 683/3463 |
| 2023 | -13.39% 1539/2656 |
11.08% 350/2280 |
-5.41% 1446/2385 |
-11.91% 2098/2515 |
-6.43% 1772/2655 |
| 2022 | -32.79% 1686/2207 |
-21.57% 1637/1919 |
1.79% 1421/2016 |
-18.32% 1695/2113 |
3.06% 777/2208 |
| 2021 | 0.21% 722/1822 |
-9.20% 1104/1255 |
19.66% 158/1330 |
-13.47% 1343/1466 |
6.59% 209/1822 |
| 2020 | - - |
- - |
31.50% 39/1067 |
7.61% 768/1164 |
15.81% 190/1184 |
| 2019 | - - |
- - |
- - |
- - |
- - |
| 2018 | - - |
- - |
- - |
- - |
- - |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 华富中证港股通创新药指数型发起式A | 1.1464 | 27.24% |
| 嘉实中证港股通创新药指数发起式C | 0.8441 | 26.80% |
| 中欧中证港股通创新药指数发起A | 1.5868 | 26.75% |
| 中欧中证港股通创新药指数发起C | 1.4370 | 26.67% |
| 永赢中证港股通医疗主题ETF发起联接A | 0.8762 | 26.58% |
| 华夏中证港股通医疗主题ETF发起式联接A | 0.8585 | 26.45% |
| 华夏中证港股通医疗主题ETF发起式联接C | 0.8568 | 26.39% |
| 易方达中证科技50ETF VS. 长安沪深300非周期A(740101) |